nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—SLC22A1—Estropipate—osteoporosis	0.156	0.215	CbGbCtD
Prazosin—SLC22A3—Estradiol—osteoporosis	0.126	0.173	CbGbCtD
Prazosin—SLC22A2—Estradiol—osteoporosis	0.0744	0.103	CbGbCtD
Prazosin—SLC22A1—Estradiol—osteoporosis	0.0646	0.0892	CbGbCtD
Prazosin—CYP1A1—Cholecalciferol—osteoporosis	0.0629	0.0868	CbGbCtD
Prazosin—ABCG2—Conjugated Estrogens—osteoporosis	0.0625	0.0863	CbGbCtD
Prazosin—ABCG2—Estradiol—osteoporosis	0.0549	0.0758	CbGbCtD
Prazosin—CYP1A1—Estradiol—osteoporosis	0.0507	0.07	CbGbCtD
Prazosin—ABCB1—Ethinyl Estradiol—osteoporosis	0.0307	0.0424	CbGbCtD
Prazosin—ABCB1—Conjugated Estrogens—osteoporosis	0.0225	0.0311	CbGbCtD
Prazosin—ABCB1—Estradiol—osteoporosis	0.0198	0.0273	CbGbCtD
Prazosin—Insomnia—Calcitriol—osteoporosis	0.000636	0.00287	CcSEcCtD
Prazosin—Constipation—Alendronate—osteoporosis	0.000631	0.00285	CcSEcCtD
Prazosin—Pain—Alendronate—osteoporosis	0.000631	0.00285	CcSEcCtD
Prazosin—Discomfort—Ethinyl Estradiol—osteoporosis	0.000626	0.00282	CcSEcCtD
Prazosin—Somnolence—Calcitriol—osteoporosis	0.000626	0.00282	CcSEcCtD
Prazosin—Malaise—Pamidronate—osteoporosis	0.000622	0.0028	CcSEcCtD
Prazosin—Pain—Raloxifene—osteoporosis	0.000621	0.0028	CcSEcCtD
Prazosin—Fatigue—Ibandronate—osteoporosis	0.00062	0.00279	CcSEcCtD
Prazosin—Syncope—Pamidronate—osteoporosis	0.000619	0.00279	CcSEcCtD
Prazosin—Arthralgia—Risedronate—osteoporosis	0.000618	0.00279	CcSEcCtD
Prazosin—Alopecia—Conjugated Estrogens—osteoporosis	0.000616	0.00278	CcSEcCtD
Prazosin—Pain—Ibandronate—osteoporosis	0.000615	0.00277	CcSEcCtD
Prazosin—Constipation—Ibandronate—osteoporosis	0.000615	0.00277	CcSEcCtD
Prazosin—Pruritus—Etidronic acid—osteoporosis	0.000613	0.00276	CcSEcCtD
Prazosin—Feeling abnormal—Alendronate—osteoporosis	0.000608	0.00274	CcSEcCtD
Prazosin—Oedema—Ethinyl Estradiol—osteoporosis	0.000608	0.00274	CcSEcCtD
Prazosin—Loss of consciousness—Pamidronate—osteoporosis	0.000606	0.00273	CcSEcCtD
Prazosin—Dry mouth—Risedronate—osteoporosis	0.000604	0.00272	CcSEcCtD
Prazosin—Pain—Calcitriol—osteoporosis	0.000602	0.00271	CcSEcCtD
Prazosin—Constipation—Calcitriol—osteoporosis	0.000602	0.00271	CcSEcCtD
Prazosin—Tension—Conjugated Estrogens—osteoporosis	0.000595	0.00268	CcSEcCtD
Prazosin—Urticaria—Estropipate—osteoporosis	0.000595	0.00268	CcSEcCtD
Prazosin—Vision blurred—Zoledronate—osteoporosis	0.000594	0.00268	CcSEcCtD
Prazosin—Diarrhoea—Etidronic acid—osteoporosis	0.000593	0.00267	CcSEcCtD
Prazosin—Body temperature increased—Estropipate—osteoporosis	0.000593	0.00267	CcSEcCtD
Prazosin—Feeling abnormal—Ibandronate—osteoporosis	0.000592	0.00267	CcSEcCtD
Prazosin—Nervousness—Conjugated Estrogens—osteoporosis	0.000589	0.00266	CcSEcCtD
Prazosin—Arthralgia—Pamidronate—osteoporosis	0.000587	0.00265	CcSEcCtD
Prazosin—Urticaria—Alendronate—osteoporosis	0.000586	0.00264	CcSEcCtD
Prazosin—Epistaxis—Estradiol—osteoporosis	0.000586	0.00264	CcSEcCtD
Prazosin—Ill-defined disorder—Zoledronate—osteoporosis	0.000585	0.00264	CcSEcCtD
Prazosin—Body temperature increased—Alendronate—osteoporosis	0.000584	0.00263	CcSEcCtD
Prazosin—Shock—Risedronate—osteoporosis	0.000583	0.00263	CcSEcCtD
Prazosin—Discomfort—Pamidronate—osteoporosis	0.00058	0.00262	CcSEcCtD
Prazosin—Body temperature increased—Raloxifene—osteoporosis	0.000574	0.00259	CcSEcCtD
Prazosin—Vision blurred—Conjugated Estrogens—osteoporosis	0.000572	0.00258	CcSEcCtD
Prazosin—Urticaria—Ibandronate—osteoporosis	0.000571	0.00257	CcSEcCtD
Prazosin—Malaise—Zoledronate—osteoporosis	0.000568	0.00256	CcSEcCtD
Prazosin—Body temperature increased—Ibandronate—osteoporosis	0.000568	0.00256	CcSEcCtD
Prazosin—Vertigo—Zoledronate—osteoporosis	0.000566	0.00255	CcSEcCtD
Prazosin—Syncope—Zoledronate—osteoporosis	0.000565	0.00255	CcSEcCtD
Prazosin—Oedema—Pamidronate—osteoporosis	0.000563	0.00254	CcSEcCtD
Prazosin—Urticaria—Calcitriol—osteoporosis	0.000559	0.00252	CcSEcCtD
Prazosin—Palpitations—Zoledronate—osteoporosis	0.000557	0.00251	CcSEcCtD
Prazosin—Body temperature increased—Calcitriol—osteoporosis	0.000556	0.00251	CcSEcCtD
Prazosin—Shock—Pamidronate—osteoporosis	0.000554	0.0025	CcSEcCtD
Prazosin—Loss of consciousness—Zoledronate—osteoporosis	0.000554	0.0025	CcSEcCtD
Prazosin—Hypersensitivity—Estropipate—osteoporosis	0.000552	0.00249	CcSEcCtD
Prazosin—Vomiting—Etidronic acid—osteoporosis	0.000551	0.00248	CcSEcCtD
Prazosin—Tachycardia—Pamidronate—osteoporosis	0.00055	0.00248	CcSEcCtD
Prazosin—Rash—Etidronic acid—osteoporosis	0.000546	0.00246	CcSEcCtD
Prazosin—Dermatitis—Etidronic acid—osteoporosis	0.000546	0.00246	CcSEcCtD
Prazosin—Vertigo—Conjugated Estrogens—osteoporosis	0.000545	0.00246	CcSEcCtD
Prazosin—Hyperhidrosis—Pamidronate—osteoporosis	0.000544	0.00245	CcSEcCtD
Prazosin—Syncope—Conjugated Estrogens—osteoporosis	0.000544	0.00245	CcSEcCtD
Prazosin—Hypersensitivity—Alendronate—osteoporosis	0.000544	0.00245	CcSEcCtD
Prazosin—Headache—Etidronic acid—osteoporosis	0.000543	0.00245	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00054	0.00243	CcSEcCtD
Prazosin—Asthenia—Estropipate—osteoporosis	0.000538	0.00242	CcSEcCtD
Prazosin—Arthralgia—Zoledronate—osteoporosis	0.000537	0.00242	CcSEcCtD
Prazosin—Palpitations—Conjugated Estrogens—osteoporosis	0.000536	0.00242	CcSEcCtD
Prazosin—Insomnia—Risedronate—osteoporosis	0.000536	0.00241	CcSEcCtD
Prazosin—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000533	0.0024	CcSEcCtD
Prazosin—Paraesthesia—Risedronate—osteoporosis	0.000532	0.0024	CcSEcCtD
Prazosin—Pruritus—Estropipate—osteoporosis	0.00053	0.00239	CcSEcCtD
Prazosin—Discomfort—Zoledronate—osteoporosis	0.00053	0.00239	CcSEcCtD
Prazosin—Asthenia—Alendronate—osteoporosis	0.00053	0.00239	CcSEcCtD
Prazosin—Hypersensitivity—Ibandronate—osteoporosis	0.00053	0.00239	CcSEcCtD
Prazosin—Dyspnoea—Risedronate—osteoporosis	0.000528	0.00238	CcSEcCtD
Prazosin—Dry mouth—Zoledronate—osteoporosis	0.000525	0.00237	CcSEcCtD
Prazosin—Fatigue—Ethinyl Estradiol—osteoporosis	0.000524	0.00236	CcSEcCtD
Prazosin—Pruritus—Alendronate—osteoporosis	0.000522	0.00235	CcSEcCtD
Prazosin—Tinnitus—Estradiol—osteoporosis	0.00052	0.00234	CcSEcCtD
Prazosin—Constipation—Ethinyl Estradiol—osteoporosis	0.00052	0.00234	CcSEcCtD
Prazosin—Hypersensitivity—Calcitriol—osteoporosis	0.000518	0.00234	CcSEcCtD
Prazosin—Flushing—Estradiol—osteoporosis	0.000518	0.00233	CcSEcCtD
Prazosin—Arthralgia—Conjugated Estrogens—osteoporosis	0.000517	0.00233	CcSEcCtD
Prazosin—Asthenia—Ibandronate—osteoporosis	0.000516	0.00232	CcSEcCtD
Prazosin—Nausea—Etidronic acid—osteoporosis	0.000515	0.00232	CcSEcCtD
Prazosin—Oedema—Zoledronate—osteoporosis	0.000514	0.00232	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000513	0.00231	CcSEcCtD
Prazosin—Diarrhoea—Estropipate—osteoporosis	0.000513	0.00231	CcSEcCtD
Prazosin—Fatigue—Risedronate—osteoporosis	0.000511	0.0023	CcSEcCtD
Prazosin—Insomnia—Pamidronate—osteoporosis	0.000509	0.0023	CcSEcCtD
Prazosin—Pruritus—Ibandronate—osteoporosis	0.000509	0.00229	CcSEcCtD
Prazosin—Pain—Risedronate—osteoporosis	0.000507	0.00228	CcSEcCtD
Prazosin—Constipation—Risedronate—osteoporosis	0.000507	0.00228	CcSEcCtD
Prazosin—Shock—Zoledronate—osteoporosis	0.000506	0.00228	CcSEcCtD
Prazosin—Paraesthesia—Pamidronate—osteoporosis	0.000506	0.00228	CcSEcCtD
Prazosin—Diarrhoea—Alendronate—osteoporosis	0.000505	0.00228	CcSEcCtD
Prazosin—Asthenia—Calcitriol—osteoporosis	0.000505	0.00228	CcSEcCtD
Prazosin—Dyspnoea—Pamidronate—osteoporosis	0.000502	0.00226	CcSEcCtD
Prazosin—Tachycardia—Zoledronate—osteoporosis	0.000502	0.00226	CcSEcCtD
Prazosin—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000501	0.00226	CcSEcCtD
Prazosin—Somnolence—Pamidronate—osteoporosis	0.000501	0.00226	CcSEcCtD
Prazosin—Pruritus—Calcitriol—osteoporosis	0.000498	0.00224	CcSEcCtD
Prazosin—Hyperhidrosis—Zoledronate—osteoporosis	0.000497	0.00224	CcSEcCtD
Prazosin—Diarrhoea—Raloxifene—osteoporosis	0.000497	0.00224	CcSEcCtD
Prazosin—Dizziness—Estropipate—osteoporosis	0.000496	0.00223	CcSEcCtD
Prazosin—Oedema—Conjugated Estrogens—osteoporosis	0.000495	0.00223	CcSEcCtD
Prazosin—Alopecia—Estradiol—osteoporosis	0.000493	0.00222	CcSEcCtD
Prazosin—Diarrhoea—Ibandronate—osteoporosis	0.000492	0.00222	CcSEcCtD
Prazosin—Dizziness—Alendronate—osteoporosis	0.000488	0.0022	CcSEcCtD
Prazosin—Shock—Conjugated Estrogens—osteoporosis	0.000487	0.0022	CcSEcCtD
Prazosin—Fatigue—Pamidronate—osteoporosis	0.000485	0.00219	CcSEcCtD
Prazosin—Tachycardia—Conjugated Estrogens—osteoporosis	0.000483	0.00218	CcSEcCtD
Prazosin—Urticaria—Ethinyl Estradiol—osteoporosis	0.000483	0.00218	CcSEcCtD
Prazosin—Constipation—Pamidronate—osteoporosis	0.000482	0.00217	CcSEcCtD
Prazosin—Pain—Pamidronate—osteoporosis	0.000482	0.00217	CcSEcCtD
Prazosin—Diarrhoea—Calcitriol—osteoporosis	0.000481	0.00217	CcSEcCtD
Prazosin—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00048	0.00216	CcSEcCtD
Prazosin—Dizziness—Raloxifene—osteoporosis	0.00048	0.00216	CcSEcCtD
Prazosin—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000479	0.00216	CcSEcCtD
Prazosin—Tension—Estradiol—osteoporosis	0.000477	0.00215	CcSEcCtD
Prazosin—Vomiting—Estropipate—osteoporosis	0.000477	0.00215	CcSEcCtD
Prazosin—Dizziness—Ibandronate—osteoporosis	0.000475	0.00214	CcSEcCtD
Prazosin—Rash—Estropipate—osteoporosis	0.000473	0.00213	CcSEcCtD
Prazosin—Dermatitis—Estropipate—osteoporosis	0.000472	0.00213	CcSEcCtD
Prazosin—Nervousness—Estradiol—osteoporosis	0.000472	0.00213	CcSEcCtD
Prazosin—Urticaria—Risedronate—osteoporosis	0.000471	0.00212	CcSEcCtD
Prazosin—Headache—Estropipate—osteoporosis	0.00047	0.00212	CcSEcCtD
Prazosin—Vomiting—Alendronate—osteoporosis	0.000469	0.00212	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000469	0.00211	CcSEcCtD
Prazosin—Body temperature increased—Risedronate—osteoporosis	0.000468	0.00211	CcSEcCtD
Prazosin—Rash—Alendronate—osteoporosis	0.000465	0.0021	CcSEcCtD
Prazosin—Insomnia—Zoledronate—osteoporosis	0.000465	0.0021	CcSEcCtD
Prazosin—Dermatitis—Alendronate—osteoporosis	0.000465	0.0021	CcSEcCtD
Prazosin—Feeling abnormal—Pamidronate—osteoporosis	0.000464	0.00209	CcSEcCtD
Prazosin—Headache—Alendronate—osteoporosis	0.000462	0.00208	CcSEcCtD
Prazosin—Paraesthesia—Zoledronate—osteoporosis	0.000462	0.00208	CcSEcCtD
Prazosin—Vomiting—Raloxifene—osteoporosis	0.000462	0.00208	CcSEcCtD
Prazosin—Dyspnoea—Zoledronate—osteoporosis	0.000459	0.00207	CcSEcCtD
Prazosin—Rash—Raloxifene—osteoporosis	0.000458	0.00206	CcSEcCtD
Prazosin—Dermatitis—Raloxifene—osteoporosis	0.000457	0.00206	CcSEcCtD
Prazosin—Somnolence—Zoledronate—osteoporosis	0.000457	0.00206	CcSEcCtD
Prazosin—Vomiting—Ibandronate—osteoporosis	0.000457	0.00206	CcSEcCtD
Prazosin—Headache—Raloxifene—osteoporosis	0.000455	0.00205	CcSEcCtD
Prazosin—Rash—Ibandronate—osteoporosis	0.000453	0.00204	CcSEcCtD
Prazosin—Dermatitis—Ibandronate—osteoporosis	0.000453	0.00204	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000451	0.00203	CcSEcCtD
Prazosin—Ill-defined disorder—Estradiol—osteoporosis	0.000451	0.00203	CcSEcCtD
Prazosin—Headache—Ibandronate—osteoporosis	0.00045	0.00203	CcSEcCtD
Prazosin—Insomnia—Conjugated Estrogens—osteoporosis	0.000448	0.00202	CcSEcCtD
Prazosin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000448	0.00202	CcSEcCtD
Prazosin—Vomiting—Calcitriol—osteoporosis	0.000447	0.00202	CcSEcCtD
Prazosin—Nausea—Estropipate—osteoporosis	0.000445	0.00201	CcSEcCtD
Prazosin—Body temperature increased—Pamidronate—osteoporosis	0.000445	0.00201	CcSEcCtD
Prazosin—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000445	0.002	CcSEcCtD
Prazosin—Rash—Calcitriol—osteoporosis	0.000444	0.002	CcSEcCtD
Prazosin—Fatigue—Zoledronate—osteoporosis	0.000443	0.002	CcSEcCtD
Prazosin—Dermatitis—Calcitriol—osteoporosis	0.000443	0.002	CcSEcCtD
Prazosin—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000442	0.00199	CcSEcCtD
Prazosin—Headache—Calcitriol—osteoporosis	0.000441	0.00199	CcSEcCtD
Prazosin—Somnolence—Conjugated Estrogens—osteoporosis	0.00044	0.00198	CcSEcCtD
Prazosin—Constipation—Zoledronate—osteoporosis	0.00044	0.00198	CcSEcCtD
Prazosin—Pain—Zoledronate—osteoporosis	0.00044	0.00198	CcSEcCtD
Prazosin—Nausea—Alendronate—osteoporosis	0.000439	0.00198	CcSEcCtD
Prazosin—Malaise—Estradiol—osteoporosis	0.000438	0.00197	CcSEcCtD
Prazosin—Hypersensitivity—Risedronate—osteoporosis	0.000436	0.00197	CcSEcCtD
Prazosin—Vertigo—Estradiol—osteoporosis	0.000436	0.00197	CcSEcCtD
Prazosin—Asthenia—Ethinyl Estradiol—osteoporosis	0.000436	0.00196	CcSEcCtD
Prazosin—Syncope—Estradiol—osteoporosis	0.000436	0.00196	CcSEcCtD
Prazosin—Nausea—Raloxifene—osteoporosis	0.000431	0.00194	CcSEcCtD
Prazosin—Pruritus—Ethinyl Estradiol—osteoporosis	0.00043	0.00194	CcSEcCtD
Prazosin—Palpitations—Estradiol—osteoporosis	0.000429	0.00193	CcSEcCtD
Prazosin—Fatigue—Conjugated Estrogens—osteoporosis	0.000427	0.00192	CcSEcCtD
Prazosin—Nausea—Ibandronate—osteoporosis	0.000427	0.00192	CcSEcCtD
Prazosin—Loss of consciousness—Estradiol—osteoporosis	0.000427	0.00192	CcSEcCtD
Prazosin—Asthenia—Risedronate—osteoporosis	0.000425	0.00192	CcSEcCtD
Prazosin—Feeling abnormal—Zoledronate—osteoporosis	0.000424	0.00191	CcSEcCtD
Prazosin—Pain—Conjugated Estrogens—osteoporosis	0.000424	0.00191	CcSEcCtD
Prazosin—Constipation—Conjugated Estrogens—osteoporosis	0.000424	0.00191	CcSEcCtD
Prazosin—Pruritus—Risedronate—osteoporosis	0.000419	0.00189	CcSEcCtD
Prazosin—Nausea—Calcitriol—osteoporosis	0.000418	0.00188	CcSEcCtD
Prazosin—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000416	0.00187	CcSEcCtD
Prazosin—Hypersensitivity—Pamidronate—osteoporosis	0.000415	0.00187	CcSEcCtD
Prazosin—Arthralgia—Estradiol—osteoporosis	0.000413	0.00186	CcSEcCtD
Prazosin—Urticaria—Zoledronate—osteoporosis	0.000409	0.00184	CcSEcCtD
Prazosin—Discomfort—Estradiol—osteoporosis	0.000409	0.00184	CcSEcCtD
Prazosin—Body temperature increased—Zoledronate—osteoporosis	0.000407	0.00183	CcSEcCtD
Prazosin—Diarrhoea—Risedronate—osteoporosis	0.000405	0.00183	CcSEcCtD
Prazosin—Dry mouth—Estradiol—osteoporosis	0.000404	0.00182	CcSEcCtD
Prazosin—Asthenia—Pamidronate—osteoporosis	0.000404	0.00182	CcSEcCtD
Prazosin—Dizziness—Ethinyl Estradiol—osteoporosis	0.000402	0.00181	CcSEcCtD
Prazosin—Pruritus—Pamidronate—osteoporosis	0.000398	0.0018	CcSEcCtD
Prazosin—Oedema—Estradiol—osteoporosis	0.000396	0.00179	CcSEcCtD
Prazosin—Urticaria—Conjugated Estrogens—osteoporosis	0.000393	0.00177	CcSEcCtD
Prazosin—Dizziness—Risedronate—osteoporosis	0.000392	0.00177	CcSEcCtD
Prazosin—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000392	0.00176	CcSEcCtD
Prazosin—Shock—Estradiol—osteoporosis	0.00039	0.00176	CcSEcCtD
Prazosin—Tachycardia—Estradiol—osteoporosis	0.000387	0.00174	CcSEcCtD
Prazosin—Vomiting—Ethinyl Estradiol—osteoporosis	0.000386	0.00174	CcSEcCtD
Prazosin—Diarrhoea—Pamidronate—osteoporosis	0.000385	0.00174	CcSEcCtD
Prazosin—Hyperhidrosis—Estradiol—osteoporosis	0.000383	0.00173	CcSEcCtD
Prazosin—Rash—Ethinyl Estradiol—osteoporosis	0.000383	0.00173	CcSEcCtD
Prazosin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000383	0.00173	CcSEcCtD
Prazosin—Headache—Ethinyl Estradiol—osteoporosis	0.000381	0.00172	CcSEcCtD
Prazosin—Hypersensitivity—Zoledronate—osteoporosis	0.000379	0.00171	CcSEcCtD
Prazosin—Vomiting—Risedronate—osteoporosis	0.000377	0.0017	CcSEcCtD
Prazosin—Rash—Risedronate—osteoporosis	0.000373	0.00168	CcSEcCtD
Prazosin—Dermatitis—Risedronate—osteoporosis	0.000373	0.00168	CcSEcCtD
Prazosin—Dizziness—Pamidronate—osteoporosis	0.000372	0.00168	CcSEcCtD
Prazosin—Headache—Risedronate—osteoporosis	0.000371	0.00167	CcSEcCtD
Prazosin—Asthenia—Zoledronate—osteoporosis	0.000369	0.00166	CcSEcCtD
Prazosin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000365	0.00164	CcSEcCtD
Prazosin—Pruritus—Zoledronate—osteoporosis	0.000364	0.00164	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000361	0.00163	CcSEcCtD
Prazosin—Nausea—Ethinyl Estradiol—osteoporosis	0.000361	0.00163	CcSEcCtD
Prazosin—Insomnia—Estradiol—osteoporosis	0.000359	0.00162	CcSEcCtD
Prazosin—Vomiting—Pamidronate—osteoporosis	0.000358	0.00161	CcSEcCtD
Prazosin—Paraesthesia—Estradiol—osteoporosis	0.000356	0.0016	CcSEcCtD
Prazosin—Asthenia—Conjugated Estrogens—osteoporosis	0.000355	0.0016	CcSEcCtD
Prazosin—Rash—Pamidronate—osteoporosis	0.000355	0.0016	CcSEcCtD
Prazosin—Dermatitis—Pamidronate—osteoporosis	0.000355	0.0016	CcSEcCtD
Prazosin—Dyspnoea—Estradiol—osteoporosis	0.000353	0.00159	CcSEcCtD
Prazosin—Headache—Pamidronate—osteoporosis	0.000353	0.00159	CcSEcCtD
Prazosin—Somnolence—Estradiol—osteoporosis	0.000352	0.00159	CcSEcCtD
Prazosin—Diarrhoea—Zoledronate—osteoporosis	0.000352	0.00159	CcSEcCtD
Prazosin—Nausea—Risedronate—osteoporosis	0.000352	0.00159	CcSEcCtD
Prazosin—Pruritus—Conjugated Estrogens—osteoporosis	0.00035	0.00158	CcSEcCtD
Prazosin—Fatigue—Estradiol—osteoporosis	0.000342	0.00154	CcSEcCtD
Prazosin—Dizziness—Zoledronate—osteoporosis	0.00034	0.00153	CcSEcCtD
Prazosin—Pain—Estradiol—osteoporosis	0.000339	0.00153	CcSEcCtD
Prazosin—Constipation—Estradiol—osteoporosis	0.000339	0.00153	CcSEcCtD
Prazosin—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000339	0.00153	CcSEcCtD
Prazosin—Nausea—Pamidronate—osteoporosis	0.000334	0.00151	CcSEcCtD
Prazosin—Dizziness—Conjugated Estrogens—osteoporosis	0.000328	0.00148	CcSEcCtD
Prazosin—Vomiting—Zoledronate—osteoporosis	0.000327	0.00147	CcSEcCtD
Prazosin—Feeling abnormal—Estradiol—osteoporosis	0.000327	0.00147	CcSEcCtD
Prazosin—Rash—Zoledronate—osteoporosis	0.000324	0.00146	CcSEcCtD
Prazosin—Dermatitis—Zoledronate—osteoporosis	0.000324	0.00146	CcSEcCtD
Prazosin—Headache—Zoledronate—osteoporosis	0.000322	0.00145	CcSEcCtD
Prazosin—Vomiting—Conjugated Estrogens—osteoporosis	0.000315	0.00142	CcSEcCtD
Prazosin—Urticaria—Estradiol—osteoporosis	0.000315	0.00142	CcSEcCtD
Prazosin—Body temperature increased—Estradiol—osteoporosis	0.000313	0.00141	CcSEcCtD
Prazosin—Rash—Conjugated Estrogens—osteoporosis	0.000312	0.00141	CcSEcCtD
Prazosin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000312	0.00141	CcSEcCtD
Prazosin—Headache—Conjugated Estrogens—osteoporosis	0.00031	0.0014	CcSEcCtD
Prazosin—Nausea—Zoledronate—osteoporosis	0.000306	0.00138	CcSEcCtD
Prazosin—Nausea—Conjugated Estrogens—osteoporosis	0.000294	0.00133	CcSEcCtD
Prazosin—Hypersensitivity—Estradiol—osteoporosis	0.000292	0.00132	CcSEcCtD
Prazosin—Asthenia—Estradiol—osteoporosis	0.000284	0.00128	CcSEcCtD
Prazosin—Pruritus—Estradiol—osteoporosis	0.00028	0.00126	CcSEcCtD
Prazosin—Diarrhoea—Estradiol—osteoporosis	0.000271	0.00122	CcSEcCtD
Prazosin—Dizziness—Estradiol—osteoporosis	0.000262	0.00118	CcSEcCtD
Prazosin—Vomiting—Estradiol—osteoporosis	0.000252	0.00114	CcSEcCtD
Prazosin—Rash—Estradiol—osteoporosis	0.00025	0.00113	CcSEcCtD
Prazosin—Dermatitis—Estradiol—osteoporosis	0.00025	0.00113	CcSEcCtD
Prazosin—Headache—Estradiol—osteoporosis	0.000248	0.00112	CcSEcCtD
Prazosin—Nausea—Estradiol—osteoporosis	0.000235	0.00106	CcSEcCtD
Prazosin—ADRA1D—Signaling Pathways—FGB—osteoporosis	2.22e-05	0.00041	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CNR2—osteoporosis	2.21e-05	0.000409	CbGpPWpGaD
Prazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.2e-05	0.000407	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—RAP1A—osteoporosis	2.2e-05	0.000407	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—FGA—osteoporosis	2.2e-05	0.000407	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—ADCY5—osteoporosis	2.2e-05	0.000406	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—WNT1—osteoporosis	2.18e-05	0.000404	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NFATC1—osteoporosis	2.18e-05	0.000403	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—ADCY5—osteoporosis	2.17e-05	0.000401	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—DKK1—osteoporosis	2.16e-05	0.000399	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—MTHFR—osteoporosis	2.16e-05	0.000399	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PSMA5—osteoporosis	2.14e-05	0.000396	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PSMA2—osteoporosis	2.14e-05	0.000396	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—FGA—osteoporosis	2.12e-05	0.000393	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—TPI1—osteoporosis	2.12e-05	0.000392	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KL—osteoporosis	2.12e-05	0.000392	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—ENO1—osteoporosis	2.1e-05	0.000389	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—ADCY5—osteoporosis	2.09e-05	0.000387	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—WNT1—osteoporosis	2.08e-05	0.000385	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—P4HB—osteoporosis	2.07e-05	0.000383	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PSMA2—osteoporosis	2.07e-05	0.000383	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PSMA5—osteoporosis	2.07e-05	0.000383	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—POMC—osteoporosis	2.06e-05	0.000382	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTHLH—osteoporosis	2.05e-05	0.000379	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—BMP2—osteoporosis	2.05e-05	0.000379	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—IGF1—osteoporosis	2.03e-05	0.000375	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—FGA—osteoporosis	2.02e-05	0.000374	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTH—osteoporosis	2.02e-05	0.000373	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—IL6R—osteoporosis	2.01e-05	0.000373	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—FGB—osteoporosis	2e-05	0.00037	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CALCA—osteoporosis	1.99e-05	0.000369	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—P4HB—osteoporosis	1.99e-05	0.000369	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—ADCY5—osteoporosis	1.99e-05	0.000369	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—IDH2—osteoporosis	1.99e-05	0.000369	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RAP1A—osteoporosis	1.98e-05	0.000367	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—BMP2—osteoporosis	1.97e-05	0.000365	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTHLH—osteoporosis	1.97e-05	0.000365	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CNR2—osteoporosis	1.96e-05	0.000364	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GAPDH—osteoporosis	1.96e-05	0.000362	CbGpPWpGaD
Prazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.96e-05	0.000362	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—ADCY5—osteoporosis	1.95e-05	0.000361	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—POMC—osteoporosis	1.95e-05	0.00036	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NFATC1—osteoporosis	1.93e-05	0.000358	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PSMA2—osteoporosis	1.93e-05	0.000358	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PSMA5—osteoporosis	1.93e-05	0.000358	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—FGB—osteoporosis	1.93e-05	0.000358	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—P4HB—osteoporosis	1.93e-05	0.000356	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—DKK1—osteoporosis	1.92e-05	0.000355	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—RAP1A—osteoporosis	1.91e-05	0.000353	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTHLH—osteoporosis	1.88e-05	0.000348	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—BMP2—osteoporosis	1.88e-05	0.000348	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTH—osteoporosis	1.87e-05	0.000347	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CYP27A1—osteoporosis	1.87e-05	0.000347	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PSMA2—osteoporosis	1.87e-05	0.000345	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PSMA5—osteoporosis	1.87e-05	0.000345	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—WNT1—osteoporosis	1.85e-05	0.000342	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	1.84e-05	0.000341	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—FGB—osteoporosis	1.84e-05	0.000341	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.84e-05	0.00034	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.83e-05	0.000339	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CNR2—osteoporosis	1.83e-05	0.000338	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ACP5—osteoporosis	1.82e-05	0.000337	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—CYP19A1—osteoporosis	1.82e-05	0.000337	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	1.81e-05	0.000335	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KL—osteoporosis	1.81e-05	0.000335	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CALCA—osteoporosis	1.8e-05	0.000333	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—CYP19A1—osteoporosis	1.8e-05	0.000333	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGA—osteoporosis	1.8e-05	0.000332	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	1.8e-05	0.000332	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—DKK1—osteoporosis	1.78e-05	0.00033	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—ENO1—osteoporosis	1.78e-05	0.000329	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PSMA2—osteoporosis	1.78e-05	0.000329	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PSMA5—osteoporosis	1.78e-05	0.000329	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—ADCY5—osteoporosis	1.77e-05	0.000328	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—POMC—osteoporosis	1.77e-05	0.000327	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—POMC—osteoporosis	1.76e-05	0.000325	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PSMA2—osteoporosis	1.75e-05	0.000324	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PSMA5—osteoporosis	1.75e-05	0.000324	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CALCA—osteoporosis	1.74e-05	0.000322	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—POMC—osteoporosis	1.73e-05	0.000319	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL6R—osteoporosis	1.72e-05	0.000319	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—WNT1—osteoporosis	1.72e-05	0.000318	CbGpPWpGaD
Prazosin—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.72e-05	0.000318	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.71e-05	0.000317	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—POMC—osteoporosis	1.7e-05	0.000314	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—TPI1—osteoporosis	1.69e-05	0.000313	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—CYP19A1—osteoporosis	1.68e-05	0.000311	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTHLH—osteoporosis	1.67e-05	0.000309	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—BMP2—osteoporosis	1.67e-05	0.000309	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGA—osteoporosis	1.67e-05	0.000309	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.66e-05	0.000308	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—ADCY5—osteoporosis	1.66e-05	0.000307	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CALCA—osteoporosis	1.66e-05	0.000306	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	1.65e-05	0.000304	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KL—osteoporosis	1.64e-05	0.000303	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGB—osteoporosis	1.63e-05	0.000302	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—POMC—osteoporosis	1.61e-05	0.000299	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—SPP1—osteoporosis	1.6e-05	0.000297	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—TGFB1—osteoporosis	1.6e-05	0.000297	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—POMC—osteoporosis	1.6e-05	0.000295	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—P4HB—osteoporosis	1.59e-05	0.000295	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KL—osteoporosis	1.58e-05	0.000292	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	1.58e-05	0.000292	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	1.58e-05	0.000292	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GAPDH—osteoporosis	1.56e-05	0.000289	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6R—osteoporosis	1.56e-05	0.000288	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	1.55e-05	0.000287	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BMP2—osteoporosis	1.55e-05	0.000287	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ENO1—osteoporosis	1.54e-05	0.000285	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—POMC—osteoporosis	1.54e-05	0.000285	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—RAP1A—osteoporosis	1.52e-05	0.000282	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGB—osteoporosis	1.52e-05	0.000281	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PSMA2—osteoporosis	1.52e-05	0.000281	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PSMA5—osteoporosis	1.52e-05	0.000281	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KL—osteoporosis	1.5e-05	0.000278	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6R—osteoporosis	1.5e-05	0.000278	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—ADCY5—osteoporosis	1.49e-05	0.000275	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—GPX1—osteoporosis	1.48e-05	0.000274	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—ADCY5—osteoporosis	1.47e-05	0.000272	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CALCA—osteoporosis	1.47e-05	0.000272	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—POMC—osteoporosis	1.47e-05	0.000271	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—GPX1—osteoporosis	1.47e-05	0.000271	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.47e-05	0.000271	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.47e-05	0.000271	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IRS2—osteoporosis	1.45e-05	0.000268	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	1.43e-05	0.000265	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6R—osteoporosis	1.43e-05	0.000265	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—CYP19A1—osteoporosis	1.42e-05	0.000263	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—LEP—osteoporosis	1.42e-05	0.000263	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—ADCY5—osteoporosis	1.42e-05	0.000263	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SPP1—osteoporosis	1.37e-05	0.000254	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—ADCY5—osteoporosis	1.37e-05	0.000254	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—MTHFR—osteoporosis	1.37e-05	0.000253	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—GPX1—osteoporosis	1.37e-05	0.000253	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CALCA—osteoporosis	1.37e-05	0.000253	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—ESR1—osteoporosis	1.36e-05	0.000251	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—MTHFR—osteoporosis	1.35e-05	0.00025	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KL—osteoporosis	1.34e-05	0.000247	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	1.33e-05	0.000247	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—POMC—osteoporosis	1.3e-05	0.000241	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ADCY5—osteoporosis	1.28e-05	0.000237	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	1.27e-05	0.000235	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IRS1—osteoporosis	1.27e-05	0.000234	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—MTHFR—osteoporosis	1.26e-05	0.000233	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IRS2—osteoporosis	1.24e-05	0.00023	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KL—osteoporosis	1.24e-05	0.00023	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SPP1—osteoporosis	1.24e-05	0.000229	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ADCY5—osteoporosis	1.24e-05	0.000229	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CYP19A1—osteoporosis	1.23e-05	0.000228	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ENO1—osteoporosis	1.23e-05	0.000228	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—POMC—osteoporosis	1.22e-05	0.000226	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—TGFB1—osteoporosis	1.22e-05	0.000225	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—LEP—osteoporosis	1.21e-05	0.000225	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PSMA2—osteoporosis	1.21e-05	0.000224	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PSMA5—osteoporosis	1.21e-05	0.000224	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—POMC—osteoporosis	1.21e-05	0.000224	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SPP1—osteoporosis	1.2e-05	0.000221	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6R—osteoporosis	1.19e-05	0.00022	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	1.18e-05	0.000218	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ADCY5—osteoporosis	1.18e-05	0.000218	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IGF1—osteoporosis	1.17e-05	0.000217	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—ADCY5—osteoporosis	1.16e-05	0.000215	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—ESR1—osteoporosis	1.16e-05	0.000215	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—GPX1—osteoporosis	1.16e-05	0.000214	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SPP1—osteoporosis	1.14e-05	0.000211	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IRS2—osteoporosis	1.12e-05	0.000207	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—LEP—osteoporosis	1.1e-05	0.000203	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—POMC—osteoporosis	1.09e-05	0.000202	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IRS1—osteoporosis	1.08e-05	0.000201	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—POMC—osteoporosis	1.08e-05	0.0002	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IRS2—osteoporosis	1.08e-05	0.0002	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—MTHFR—osteoporosis	1.07e-05	0.000198	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—LEP—osteoporosis	1.06e-05	0.000196	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ESR1—osteoporosis	1.05e-05	0.000194	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	1.05e-05	0.000194	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—POMC—osteoporosis	1.04e-05	0.000193	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IRS2—osteoporosis	1.03e-05	0.000191	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6R—osteoporosis	1.02e-05	0.000188	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SPP1—osteoporosis	1.01e-05	0.000187	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ESR1—osteoporosis	1.01e-05	0.000187	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—POMC—osteoporosis	1.01e-05	0.000187	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—LEP—osteoporosis	1.01e-05	0.000187	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ADCY5—osteoporosis	1.01e-05	0.000186	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IGF1—osteoporosis	1e-05	0.000186	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GPX1—osteoporosis	1e-05	0.000186	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CYP19A1—osteoporosis	9.84e-06	0.000182	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IRS1—osteoporosis	9.78e-06	0.000181	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	9.72e-06	0.00018	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ESR1—osteoporosis	9.63e-06	0.000178	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IRS1—osteoporosis	9.45e-06	0.000175	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—POMC—osteoporosis	9.42e-06	0.000174	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SPP1—osteoporosis	9.4e-06	0.000174	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—MTHFR—osteoporosis	9.26e-06	0.000171	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6R—osteoporosis	9.19e-06	0.00017	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IRS2—osteoporosis	9.15e-06	0.000169	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—POMC—osteoporosis	9.1e-06	0.000168	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IGF1—osteoporosis	9.06e-06	0.000168	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IRS1—osteoporosis	9e-06	0.000166	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—IL6—osteoporosis	8.97e-06	0.000166	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—LEP—osteoporosis	8.96e-06	0.000166	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6R—osteoporosis	8.87e-06	0.000164	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IGF1—osteoporosis	8.75e-06	0.000162	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—POMC—osteoporosis	8.66e-06	0.00016	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ESR1—osteoporosis	8.55e-06	0.000158	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—POMC—osteoporosis	8.55e-06	0.000158	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IRS2—osteoporosis	8.5e-06	0.000157	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6R—osteoporosis	8.45e-06	0.000156	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IGF1—osteoporosis	8.33e-06	0.000154	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—LEP—osteoporosis	8.32e-06	0.000154	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ADCY5—osteoporosis	8.04e-06	0.000149	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GPX1—osteoporosis	8.01e-06	0.000148	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IRS1—osteoporosis	7.99e-06	0.000148	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ESR1—osteoporosis	7.95e-06	0.000147	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—POMC—osteoporosis	7.69e-06	0.000142	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL6—osteoporosis	7.68e-06	0.000142	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6R—osteoporosis	7.51e-06	0.000139	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IRS1—osteoporosis	7.42e-06	0.000137	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—POMC—osteoporosis	7.4e-06	0.000137	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1—osteoporosis	7.4e-06	0.000137	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—osteoporosis	7.39e-06	0.000137	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—POMC—osteoporosis	7.15e-06	0.000132	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—osteoporosis	7.05e-06	0.00013	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TGFB1—osteoporosis	7.03e-06	0.00013	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6R—osteoporosis	6.97e-06	0.000129	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—osteoporosis	6.93e-06	0.000128	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1—osteoporosis	6.88e-06	0.000127	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—osteoporosis	6.69e-06	0.000124	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—osteoporosis	6.37e-06	0.000118	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—osteoporosis	6.03e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TGFB1—osteoporosis	6.02e-06	0.000111	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—POMC—osteoporosis	5.91e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—osteoporosis	5.66e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—osteoporosis	5.45e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	5.43e-06	0.000101	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—osteoporosis	5.3e-06	9.81e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—osteoporosis	5.26e-06	9.73e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—osteoporosis	5.26e-06	9.73e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TGFB1—osteoporosis	5.25e-06	9.71e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—osteoporosis	5.01e-06	9.27e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	5e-06	9.24e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—osteoporosis	4.54e-06	8.39e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—osteoporosis	4.45e-06	8.23e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	4.44e-06	8.21e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—osteoporosis	4.13e-06	7.65e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	4.12e-06	7.63e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—osteoporosis	4.09e-06	7.58e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—osteoporosis	3.95e-06	7.31e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—osteoporosis	3.76e-06	6.97e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—osteoporosis	3.34e-06	6.19e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—osteoporosis	3.11e-06	5.75e-05	CbGpPWpGaD
